Phase I/II Cabazitaxel for Recurrent Malignant Glioma
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goal of Part 1 of this clinical research study is to find the highest tolerable dose of
cabazitaxel that can be given to patients with glioblastoma. The goal of Part 2 is to learn
if cabazitaxel can help to control glioblastoma. The safety of the study drug will also be
studied in both parts.
Cabazitaxel is designed to interfere with the growth of cancer cells by stopping cell
division.